This may suggest that other metabolites, perhaps precursors of thiodiglycolic acid, may be responsible for IF encephalopathy and nephropathy.
Introduction
Cyclophosphamide (CP) and ifosfamide (IF) are isomeric oxazaphosphorine cytostatic drugs used widely in the chemotherapy of various cancers. CP was developed over 50 years ago as a innovative example of a pro-drug that might be transported to the tumor and then activated by tumor-specific enzymes, a strategy that had proven valuable for the treatment of prostate carcinoma with stilbestrol diphosphate [1] . High tumor expression and activity of phosphoramidase was the rational design principle [2] that lead to the incorporation of the highly cytotoxic nornitrogen mustard (NNM) into a stable and apparently inert oxazaphosphorine ring (Fig. 1A ). It soon transpired that NNM was generated only in trace amounts but rather CP was converted in the liver into a transported metabolite that could be readily taken up by tumors [3] . A somewhat complex hepatic metabolic scheme gradually unfolded with CP converted to 4-hydroxycyclophosphamide (4OHCP) [4] , which in turn taumomerized to aldophosphamide (AP) [5] that β-eliminated AC [6] [7] to yield phosphoramide mustard (PM) [7] [8] . This pathway can readily be reconciled with other observed metabolites of CP, such as 4-oxocyclophosphamide (4-ketocyclophosphamide; 4OCP) [9] , iminocyclophosphamide (ICP) [10] , and carboxyphosphamide (CXP) [11] (Fig.   1A ). Both AP [7] and PM [11] were postulated as transport forms of CP. Ifosfamide (IF) was developed a decade after CP [12] and its metabolic transformation was reported to bear similarities to its isomer CP (Fig. 1B) . Specifically, phenobarbital-induced rat liver microsomes converted IF to AC [7, 13] after the prior formation of 4-hydroxyifosfamide (4OHIF) [7] , which was later reported to be in equilibrium with its tautomer aldoifosfamide (AIF) [14] . However, a major metabolic pathway for IF was side-chain dealkylation to yield 4 2-and 3-dechloroethylifosfamide (2-DCIF and 3-DCIF), both in vitro [7] and in vivo [15] , together with 2-chloroacetaldehyde (CAL) [16] and 2-chloroethylamine (CEA) [17] [18] .
These two-carbon metabolites had been reported at only low levels in CP-treated rodents [11, [19] [20] . Later reports demonstrated side-chain dealkylation yielding 2-DCIF and 3-DCIF as a major pathway of IF metabolism in both pediatric [21] [22] [23] and adult patients [24] [25] [26] . While the systemic toxicity of the aldehyde product of CP and IF metabolism AC had been mitigated by the introduction of mesna [27] [28] , the issue of host toxicity due to CAL was not immediately addressed [16] .
The differential metabolism of CP and IF most likely plays a central role in the differing toxicity profiles of these isomeric drugs. While the general pattern of intact oxazaphosphorine metabolites is similar for CP and IF, a key difference is the number and abundance of two-carbon metabolites that derive from side-chain dealkylation. It was proposed that CAL underlies both the neurotoxicity [16, [29] [30] and nephrotoxicity [31] of IF.
Additionally, CEA was proposed as a toxic metabolite [29] [30] and has been reported to derive directly from IF by chemical hydrolysis and also reacting with bicarbonate to form 1,3-oxazolidin-2-one [17] . CAL has been reported to be converted to 2-chloroacetic acid (CAA) by human kidney [31] and rabbit heart [32] . In turn, CAA may react with cellular thiols to yield S-carboxymethylcysteine (SCMC) and its metabolite thiodiglycolic acid (TDGA) [15] (Fig. 1B) . Other cysteine derived metabolites have also been observed [32] .
What role this panoply of small IF metabolites plays in the selective toxicity and efficacy of IF is poorly understood.
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What is clear is that CP and IF are two potent drugs which are inactive per se and whose effects on both the tumor and the host are determined by metabolism. Despite the large number of published studies on the metabolism of CP and IF both in vitro and in vivo and in a variety of species including Man (Table 1) , a comprehensive comparative analysis of their metabolism is indicated. We have chosen to do this in the mouse for the sole reason that such a study lends itself to further investigation in animals humanized for various metabolic enzymes and the nuclear receptors that regulate their tissue expression [33] . We have also employed ultra-performance chromatography-linked electrospray ionization quadrupole timeof-flight mass spectrometry (UPLC-ESI-QTOFMS), which has proven successful in studies involving metabolomic protocols to uncover unforeseen drug metabolites of PhIP [34] , melatonin [35] , aminoflavone [36] , acetaminophen [37] , and the areca alkaloids [38] [39] . 
Materials and Methods

Materials
IF (ifosfamide), CP (cyclophosphamide), SCMC (S-carboxymethylcysteine), TDGA (thiodiglycolic acid), and 4-nitrobenzoic acid were purchased from Sigma-Aldrich (St. Louis, MO). Solvents and other chemicals were of the highest grade commercially available.
Animals and treatments
Male C57BL/6 mice were obtained from the NCI-Frederick Animal Production Program. 
UPLC-ESI-QTOFMS profiling of urinary metabolites
Urine samples were prepared by mixing 10 μl of urine with 90 μl of 50% aqueous acetonitrile and centrifuging at 18,000  g for 10 min to remove protein and particulates. A 5 μl aliquot of supernatant was injected into a Waters UPLC-ESI-QTOFMS system (Milford, MA were maintained at 3 kV and 20 V, respectively. Source temperature and desolvation temperature were set at 120 °C and 350 °C, respectively. Nitrogen was used as both cone gas (50 l/h) and desolvation gas (600 l/h), and argon was used as collision gas. Sulfadimethoxine was used as the lock mass (m/z 311.0814 + ) for accurate mass calibration in real time. As for MS/MS fragmentation of target ions, collision energy ranging from 10 to 40 eV was applied.
Mass chromatograms and mass spectral data were acquired using MassLynx software Metabolites containing two chlorines would be expected to have a chlorine isotope ratio of 9:6:1.
Data processing and multivariate data analysis (MDA)
The mass chromatographic data were deconvoluted using MarkerLynx software (Waters), and a data matrix was generated for MDA. The ion intensity was calculated as the percentage of total ion counts (TIC) in the whole chromatogram. The data matrix was exported into SIMCA-P software (Umetrics, Kinnelon, NJ) for MDA. In order to separate drug metabolites 8 from endogenous metabolites in urine, the integrated ions in vehicle group and treatment group were analyzed using an orthogonal projection to latent structures (OPLS) model. OPLS analysis was conducted to represent the major latent variables in the data matrix and was described in a scores scatter plot after data were Pareto scaled. Identification of IF, CP and their metabolites was performed by analyzing the loadings plot and contribution table, as previously described [34] [35] [36] [37] [38] [39] . The general protocol for the identification of xenobiotic metabolites using metabolomics has recently been reviewed [40] .
Tandem LC-MS quantitation of SCMC and TDGA
Samples from IF-or CP-treated mice were prepared by mixing 20 μl of urine with 80 μl of 50% aqueous acetonitrile and centrifuging at 18,000  g for 10 min. 10 μl was injected for (4-nitrobenzoic acid).
LC-MS/MS analysis. LC-MS/MS analysis was performed on an
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A c c e p t e d M a n u s c r i p t 
Relative quantitation of the metabolites of IF and CP
Although the authentic standards of metabolites were unavailable, it was possible to determine their approximate abundance in the urine. Using several assumptions [38] [39] , including that the metabolites were equivalently eluted and ionized (ESI+) over the entire chromatographic range, with equivalent degrees of ion suppression, it was possible to approximate the relative excretion of IF, CP, and their metabolites in the urine. These assumptions have been validated in a metabolomics study of the metabolism of (±)-arecoline 1-oxide in the mouse [39] . However, it is accepted that such estimates of relative concentration may be error-prone.
Statistical analysis
Experimental values are expressed as mean ± standard deviation (S.D.). Statistical analysis was performed using independent Student's t tests or ANOVA. P-values less than 0.05 were considered significant.
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Results
Metabolomic analysis of mouse urine after IF and CP administration
After urine samples from the treated and control groups were analyzed by UPLC-ESI-QTOFMS, data were deconvoluted, and analyzed using OPLS. The advantage of OPLS is that the model is rotated so that class (treated and control) separation is found in the first predictive component, tp, also referred to as the correlated variation [41] . This multivariate model was built to determine the relationship between the treated and control groups, and the contribution of each detected urinary ion to the model. As shown in the scores scatter plot ( Fig. 2A-B) , urine samples from IF and CP treatment were clearly separated from the control in the first component (t [1] ), driven predominantly by the presence of drug and drug-related metabolites ( Fig. 2C-D) . The trend plots of ions from putative drug-related metabolites were used to display graphically the absence of those ions in vehicle-treated animals ( Fig. 3A-E ).
The increased ions were further determined as drug-related or endogenous metabolites based on the mass defect shifts [42] . In general, the mass defects of phase I and II drug metabolites were over the range of -50 mDa and +50 mDa compared with the parent drug. After drug metabolites were determined, their chemical structures could be elucidated through MS/MS.
Identification and structural elucidation of the urinary metabolites of IF and CP
After the metabolites were screened using OPLS and accurate mass measurement, their chemical structures were identified on the basis of the MS/MS fragmentation. Overall, IF (F1), CP (P1) and their 23 metabolites were identified in the urine samples from mice (Tables   2 and 3 generated from the loss of the hydroxyl group. The fragment at m/z 138.031 + was produced from the hydroxylation and chloroethylation of P12. The cleavage pattern was similar to the alcophosphamide. Therefore, P12 was identified as dechloroethylalcophosphamide.
Estimation of relative concentrations of IF and CP metabolites by chromatographic analysis
Based on their exact masses, peaks were extracted from the UPLC chromatograms, and areas integrated (Tables 2 and 3 ). The metabolites of IF and CP were grouped by metabolic transformation,as follows: dechloroethylation, hydroxylation, ketonization, dehydroxylation, 14 alkylation, ring-opening, and conjugation reactions ( Table 4) . As shown in Fig. 5 , the excretion of the unchanged IF in mouse urine was similar to the excretion of CP. The dechloroethylated metabolites of IF were present in higher concentrations than CP (2-fold).
The ring-opened and ketonization metabolites of CP were present at higher concentrations than IF (5-fold and 3-fold, respectively). In addition, although the hydroxylated, dehydroxylated, alkylated, and conjugated metabolites were different between IF and CP, their relative abundance in the urine was very low following treatment with either IF or CP.
Urinary excretion of SCMC and TDGA
After the treatment of mice with either IF or CP, SCMC (F12) and TDGA (F13) excretion was increased above endogenous levels. Because of their low molecular weight and weak acidity, SCMC and TDGA could be detected in negative ion mode of using UPLC-ESI-QTOF-MS. However, their concentration was determined by triple quadrupole mass spectrometry. From Fig. 6A , it can be seen that SCMC excretion was increased 32-fold and 44-fold in urine above endogenous levels, respectively, after treatment with IF and CP.
TDGA excretion was also increased in urine by 14-fold and 17-fold following IF and CP treatment, respectively. Therefore, both isomeric drugs show surprisingly similar profiles with respect to these metabolites.
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Discussion
Metabolomics is an invaluable tool for profiling biological fluids for small molecules, and with respect to pharmacology, metabolomics has provided substantial insight into drug metabolism pathways. For example, the metabolic map of acetaminophen (which had been studied for over 40 years) was recently expanded by three metabolites [37] . Similarly, the metabolic maps of IF and CP were expanded (two IF and three CP new metabolites) and 18 known metabolites that otherwise had taken over 40 years to identify (Table 1) are also reported here. This demonstrates the power of UPLC-ESI-QTOFMS-based metabolomics applied to the study of drug metabolism.
IF and CP are prodrugs that are converted to their active forms during metabolic biotransformation [43] . Their biological activity is mediated through their active metabolites, including 4-hydroxyifosfamide and 4-hydroxycyclophosphamide, both of which were detected in this study. Because of their respective equilibrium with aldoifosfamide and aldophosphamide, a minor amount of 4-hydroxyifosfamide and 4-hydroxyclophosphamide were excreted in the urine. Aldoifosfamide was both reduced and oxidized to alcoifosfamide and carboxyifosfamide, respectively, presumably by the action of alcohol dehydrogenase and aldehyde dehydrogenase [26] . In a similar manner, aldophosphamide was both reduced and oxidized to alcophosphamide and carboxyphosphamide, respectively [44] . It can be seen from Fig. 5 that ring-opened metabolites were produced to a greater extent from CP than from IF, and this was the major difference between the two drugs. However, in compensation, the dechloroethylated metabolites of IF were excreted to a greater extent than from CP. SCMC and TDGA, both normal products of endogenous metabolism, were found at A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 low concentrations in control urine. Following treatment with IF and CP, SCMC and TDGA were significantly elevated in vivo (Fig. 6) . It is known that CAA can lead to the formation of SCMC through conjugation with cysteine or glutathione, and SCMC is further transformed to TDGA [45] . SCMC has been reported to activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainite receptor and induce cellular acidification which may be responsible for the reported encephalopathy [46] [47] . In addition, TDGA can cause mitochondrial dysfunction which may also contribute to the side-effects associated with IF treatment [48] . However, there have been no reports that SCMC and TDGA resulting from the treatment by CP lead to toxicity. Here, SCMC and TDGA were detected in urine from the CP-treated mice. The generation of CAA from IF was greater than from CP, according to the significantly higher rate of N-dechloroethylation of IF (Fig. 5 ) Surprisingly therefore, there were no significant differences in SCMC and TDGA production in IF-and CP-treated mice ( Fig. 6B and D) . However, it was previously reported that TDGA is the major urinary metabolite in cancer patients treated with IF and this was suggested as the causative IF metabolite of encephalopathy [48] . Apparently, TDGA is an inconsequential urinary metabolite of CP (A. Küpfer, unpublished observation). However, TDGA was determined in these human studies by lyophilization and derivatization of urines with BF 3 /methanol at 60 ºC, in contrast to the studies described here where diluted urines were injected directly into the tandem mass spectrometer. It is therefore possible that TDGA is formed during the heating process, either by spontaneous decarboxylation of the α-keto acid of SCMC (Scarboxymethyl-3-thiopyruvic acid; SCMTPA) [46] [47] or from an acid-or heat-labile ester, such as the carnitine ester of TDGA.
Previous studies suggested that IF treatment resulted in changes in the excretion patterns of low molecular weight endogenous metabolites (hippuric acid, trimethylamine N-oxide, glycine, lactate, histidine and glucose), which were regarded as biomarkers of IF nephrotoxicity and encephalopathy [49] . The current findings suggest that IF-induced sideeffects may result directly from CAA rather than from SCMC and TDGA. Studies have reported that CAA can result in neurotoxicity and nephrotoxicity [50] [51] . This observation may offer one potential mechanism to explain IF-related neurotoxicity and nephrotoxicity.
Despite the large number of published in vitro and in vivo CP and IFO metabolism studies, five novel metabolites (F5, F11, P9, P11 and P12) were found by metabolomic analysis in this study. Iminoifosfamide from IF corresponded to iminocyclophosphamide (F6) from CP. Previous studies reported some conjugated metabolites with GSH from IF and CP, such as ifosforamide mustard and cyclophosphamide [14, 52] . However, there was no GSH conjugation detected in either urine and serum. Here, two minor glucuronide conjugate metabolites (F11 and P9) were found from IF-and CP-treated mice. Furthermore, two new Ndechloroethylated (P11 and P12) metabolites from CP were found in the urine (Fig. 8) .
Inspection of the loadings S-plot in Fig. 2D suggests that P11 has a similar abundance to the principal N-dechloroethylated metabolite P3, while P12 is a much more minor metabolite.
The metabolomic studies described here were carried out in the mouse. As shown in Table   1 , rat and human have been the principal species studied historically for CP and IF metabolism. There are relatively few data in the mouse. Nevertheless, the value of the mouse is that future studies may be conducted in genetically modified mice, that permit direct questions to be asked about the role of discrete enzymes and the nuclear receptors that control 18 their expression in the liver and other tissues [33] . It may be envisaged that data from mice humanized for CP and IF metabolizing enzyme genes could be compared with actual clinical data for these drugs, thus refining and improving animal modeling of caner chemotherapy.
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